The Effect of Simvas tatin on Uterine Fibroids Developmentand ART Outcome in Infertile Women: A PilotS tudy

Background: Uterine fibroids are the mos t common form ofbenign gynecologic tumors with a lifetime risk of around ۷۰%.S tatins are the mos t commonly prescribed lipid-lowering agentsthat have been reported to inhibit proliferation of fibroid cellsin animal model. In this s tudy, an attempt was made to comparesizes of uterine fibroids in women received simvas tatin orallyor vaginally and those received placebo undergoing ART outcome.Materials and Methods: This randomized controlled trials tudy was conducted on ۳۰ infertile women undergoing ARTcycles. Patients with presence of at leas t one intramural fibroidwith size >۴ cm or two intramural fibroids with size >۳ cm confirmedby ultrasound included the s tudy. Patients with age >۴۰ years old, body mass index (BMI) <۲۵ Kg/m۲, number offibroids ≥ ۵, any hormonal therapy in the las t ۳ months, alcoholconsumption, allergic reactions to simvas tatin, diagnosisof cancer, Hb ≤ ۷g/dl, severe male factor infertility and severeendometriosis, spontaneous pregnancy and patients with signsor symptoms of medical conditions and use of medications thatinterfere with simvas tatin excluded from the s tudy. Patientswere randomly assigned to one of the three groups of women(group A: received simvas tatin ۴۰ mg orally & placebo vaginally;group B: simvas tatin ۴۰ mg vaginally & placebo orally and group C: placebo vaginally & placebo orally) for ۳ months(۱۰ women in each group). The primary outcome measure wasuterine fibroid size and secondary outcome measures were uterinesize and reproductive outcome after ART. For data analysis,S tATA software was used. In all tes ts, the significance level wasconsidered less than ۰.۰۵.Results: All groups were comparable in regards to mean age,BMI, infertility duration, type and causes of infertility. Therewere no s tatis tical differences between groups in respect to sizesand volume of fibroids and dimensions and volume of uterusbefore and after treatment. Although the rate of clinical pregnancywas higher in women who received simvas tatin ۴۰ mgorally than two other groups, this increase was not s tatis ticallysignificant (P=۰.۱۳۹).Conclusion: These data sugges t to design a further clinical trials tudy with larger sample size using different oral doses of Simvastatin.

کلیدواژه ها:

Assis ted Reproductive Technology ، Infertile ، Outcome ، Uterine Fibroids ، Simvas tatin